within Pharmacolibrary.Drugs.ATC.J;

model J05AR12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.87,
    Cl             = 0.0004783333333333333,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.019666666666666666,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AR12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lamivudine and tenofovir disoproxil are antiretroviral medications used in combination for the treatment of HIV-1 infection in adults and adolescents, and also for chronic hepatitis B infection (tenofovir). Both drugs are approved and recommended as first-line therapy by major guidelines.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters from published studies of HIV-infected adults, both sexes, receiving oral fixed-dose combination tablets of lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg once daily.</p><h4>References</h4><ol><li><p>Yee, KL, et al., &amp; Iwamoto, M (2020). Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate. <i>AAPS PharmSciTech</i> 21(3) 91–None. DOI:<a href=\"https://doi.org/10.1208/s12249-020-1630-6\">10.1208/s12249-020-1630-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32060665/\">https://pubmed.ncbi.nlm.nih.gov/32060665</a></p></li><li><p>Uglietti, A, et al., &amp; Maserati, R (2012). Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation. <i>Expert opinion on drug metabolism &amp; toxicology</i> 8(10) 1305–1314. DOI:<a href=\"https://doi.org/10.1517/17425255.2012.714367\">10.1517/17425255.2012.714367</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22943210/\">https://pubmed.ncbi.nlm.nih.gov/22943210</a></p></li><li><p>Menne, S, et al., &amp; Tennant, BC (2005). Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. <i>Antimicrobial agents and chemotherapy</i> 49(7) 2720–2728. DOI:<a href=\"https://doi.org/10.1128/AAC.49.7.2720-2728.2005\">10.1128/AAC.49.7.2720-2728.2005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15980342/\">https://pubmed.ncbi.nlm.nih.gov/15980342</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AR12;
